More importantly, loss of KDM6A in human PDA cell lines increased their sensitivity to bromodomain and extra-terminal (BET) inhibitors and G9α methyltransferase inhibitors [13]. This evidence concerns the gene KDM6A and Patent ductus arteriosus.